Cargando…

A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV

OBJECTIVES: To compare outcomes with single tablet regimens (STR) versus multi-tablet regimens (MTR) for human immunodeficiency virus (HIV) treatment using published data. DESIGN: Systematic review and random-effects meta-analysis of literature on approved and investigational HIV regimens. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clay, Patrick G., Yuet, Wei C., Moecklinghoff, Christiane H., Duchesne, Inge, Tronczyński, Krzysztof L., Shah, Sandip, Shao, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206661/ https://www.ncbi.nlm.nih.gov/pubmed/30373620 http://dx.doi.org/10.1186/s12981-018-0204-0

Ejemplares similares

New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom
por: Gazzard, Brian, et al.
Publicado: (2012)

Patients’ Willingness to Take Multiple-Tablet Antiretroviral Therapy Regimens for Treatment of HIV
por: Engelhard, Esther A. N., et al.
Publicado: (2016)

Effectiveness of antiretroviral therapy in the single-tablet regimen era
por: Costa, Juliana de Oliveira, et al.
Publicado: (2018)

Dyslipidaemia Among Children Living with HIV after 48 Weeks of First-line Antiretroviral Therapy
por: Perumal Kannabiran, Bhavani, et al.
Publicado: (2017)

Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens
por: Clay, P.G., et al.
Publicado: (2015)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Desimplification of Single Tablet Antiretroviral (ART) Regimens—A Practical Cost-Savings Strategy?
por: Krentz, Hartmut, et al.
Publicado: (2019)

550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice
por: Mills, Anthony, et al.
Publicado: (2018)

Treatment outcome of different antiretroviral drug regimens in HIV-positive pregnant women
por: Chauhan, Nidhi, et al.
Publicado: (2021)

Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice
por: Drozd, Daniel R., et al.
Publicado: (2017)

Antiretroviral treatment and expression of the mRNA levels for Pgp, MRP1, MRP4 and MRP5 in HIV antiretroviral naïve patients. Follow-up at 48 weeks
por: Falasca, Francesca, et al.
Publicado: (2010)

557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
por: Maki, Gina, et al.
Publicado: (2018)

Single Tablet Regimen Usage and Efficacy in the Treatment of HIV Infection in Australia
por: Armstrong, B., et al.
Publicado: (2015)

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
por: Lathouwers, Erkki, et al.
Publicado: (2020)

Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen
por: Colombo, Giorgio L, et al.
Publicado: (2013)

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
por: Mounzer, Karam, et al.
Publicado: (2019)

Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study
por: Chendi, Bih Hycenta, et al.
Publicado: (2019)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Effectiveness of four antiretroviral regimens for treating people living with HIV
por: Cavalcanti, Aracele Tenório de Almeida e, et al.
Publicado: (2020)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
por: Fabbiani, M, et al.
Publicado: (2012)

HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2018)

Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India
por: Sood, Ajit, et al.
Publicado: (2019)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
por: Murray, Miranda, et al.
Publicado: (2020)

Single-Tablet Regimens in HIV Therapy
por: Astuti, Noemi, et al.
Publicado: (2014)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017)

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study
por: Rossi, Maria C, et al.
Publicado: (2019)

1036. Persistence of Guideline-Recommended Antiretroviral Therapy Regimens among Persons Living with HIV Newly Initiating Treatment in the US
por: Cohen, Joshua P, et al.
Publicado: (2020)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
por: Cotte, Laurent, et al.
Publicado: (2017)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

1255. Single-tablet Regimens (STR) Offer Better Persistence and Adherence, with Lower Costs by Adherence Status, than Multiple-tablet Regimens (MTR) for People Living with HIV (PLWH) Enrolled in Medicaid
por: Brogan, Andrew P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fjpeutq1nrpkaf0qvuut2ir5vb